{"id":"vitamin-k-antagonists-vka","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Bleeding"},{"rate":"1-3%","effect":"Bruising"},{"rate":"1-2%","effect":"Nosebleeds"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism is achieved by blocking the action of vitamin K epoxide reductase complex 1 (VKORC1), which is necessary for the gamma-carboxylation of clotting factors II, VII, IX, and X. As a result, these clotting factors are not activated, and blood clotting is inhibited.","oneSentence":"Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:50.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis and pulmonary embolism prevention"}]},"trialDetails":[{"nctId":"NCT06521463","phase":"NA","title":"SIMPLAAFY Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-10-01","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":1857},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT06315530","phase":"PHASE2","title":"Effect of Telitacicept on Antibody Titers in Primary APS Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2023-12-01","conditions":"Antiphospholipid Syndrome (APS)","enrollment":20},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT07125417","phase":"PHASE4","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"OCEAN-SHD Study Group","startDate":"2025-05-29","conditions":"Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy","enrollment":500},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT03892824","phase":"NA","title":"Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Javelin Medical","startDate":"2019-04-15","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT02618577","phase":"PHASE3","title":"Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes","status":"TERMINATED","sponsor":"Atrial Fibrillation Network","startDate":"2016-02","conditions":"Atrial High Rate Episodes","enrollment":2608},{"nctId":"NCT06747312","phase":"PHASE2","title":"Effect of Belimumab on Antibody Titers in Primary APS Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-04-01","conditions":"Antiphospholipid Syndrome (APS)","enrollment":20},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2019-09-19","conditions":"Intracranial Hemorrhage","enrollment":104},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT06143787","phase":"PHASE3","title":"Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction","status":"UNKNOWN","sponsor":"Hyloris Developments","startDate":"2023-11-07","conditions":"Bleeding From Teeth, Bleeding Prophylaxis","enrollment":280},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT04001205","phase":"","title":"Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turku","startDate":"2019-06-01","conditions":"Atrial Fibrillation, Stroke, Ischemic","enrollment":1300},{"nctId":"NCT05205863","phase":"PHASE1, PHASE2","title":"Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2021-11-12","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT06179823","phase":"","title":"Safety of Direct Oral Anticoagulant During Pregnancy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2019-01-01","conditions":"Thromboembolic Disease","enrollment":1755558},{"nctId":"NCT05150938","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-03-18","conditions":"Treatment of Venous Thromboembolism in Cancer Patients","enrollment":5737},{"nctId":"NCT03826927","phase":"","title":"New Oral Anticoagulants (NOAC) in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-03-01","conditions":"Stroke, Atrial Fibrillation","enrollment":1023},{"nctId":"NCT02533960","phase":"","title":"Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime","status":"COMPLETED","sponsor":"University Hospital Heidelberg","startDate":"2015-06","conditions":"Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation","enrollment":3832},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT02353585","phase":"","title":"Novel Oral Anticoagulants in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Ischemic Stroke, Intracranial Hemorrhages","enrollment":1050},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-08-22","conditions":"Rheumatic Heart Disease","enrollment":4565},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-19","conditions":"Thrombosis","enrollment":192},{"nctId":"NCT04171726","phase":"PHASE3","title":"Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2019-08-01","conditions":"Aortic Valve Stenosis","enrollment":100},{"nctId":"NCT02663076","phase":"","title":"Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2016-04","conditions":"Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)","enrollment":1700},{"nctId":"NCT02832531","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority","status":"WITHDRAWN","sponsor":"Population Health Research Institute","startDate":"2022-01","conditions":"Rheumatic Heart Disease","enrollment":""},{"nctId":"NCT02640222","phase":"","title":"APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-01-01","conditions":"Anticoagulation","enrollment":321501},{"nctId":"NCT02507856","phase":"","title":"Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2015-07","conditions":"Brain Ischemia With Non-valvular Atrial Fibrillation, Transient Ischemic Attack With Non-valvular Atrial Fibrillation","enrollment":10044},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT03362788","phase":"","title":"The Greek AntiPlatElet Atrial Fibrillation Registry.","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2017-12-01","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":654},{"nctId":"NCT02319460","phase":"","title":"An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-04-24","conditions":"Hemorrhage","enrollment":2238},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-01","conditions":"Atrial Fibrillation","enrollment":3739},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT03150303","phase":"","title":"Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-07-04","conditions":"Oral Anticoagulants, Invasive Procedure","enrollment":532},{"nctId":"NCT03374540","phase":"","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Nonvalvular Atrial Fibrillation","enrollment":78517},{"nctId":"NCT04419012","phase":"","title":"Polish Atrial Fibrillation (POL-AF) Registry","status":"UNKNOWN","sponsor":"Jan Kochanowski University","startDate":"2019-01-06","conditions":"Atrial Fibrillation","enrollment":4000},{"nctId":"NCT03537521","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots","status":"WITHDRAWN","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-04","conditions":"Severe Bleeding, Urgent Surgery","enrollment":""},{"nctId":"NCT01722786","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2014-04","conditions":"Severe Bleeding, Urgent Surgery","enrollment":272},{"nctId":"NCT02415400","phase":"PHASE4","title":"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-06-04","conditions":"Acute Coronary Syndromes","enrollment":4614},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02596230","phase":"","title":"RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-11-05","conditions":"Venous Thromboembolism","enrollment":7797},{"nctId":"NCT04117048","phase":"NA","title":"INR at Home Measurement by the LabPad® Point-of-care in Patients on Vitamin K Antagonist Drugs (VKA)","status":"COMPLETED","sponsor":"Medicalps","startDate":"2019-10-03","conditions":"Vitamine K Antagonist (VKA) Treatment, International Normalized Ratio (INR) Measure at Home, Thromboembolic Pathology","enrollment":128},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT02839746","phase":"","title":"Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-06-13","conditions":"Atrial Fibrillation","enrollment":671},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":632},{"nctId":"NCT02684981","phase":"","title":"Patient Convenience Study (RE-SONANCE)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-11-11","conditions":"Atrial Fibrillation, Stroke","enrollment":9472},{"nctId":"NCT02849509","phase":"","title":"Patient Convenience Study- NIS RELATE","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-06-20","conditions":"Atrial Fibrillation","enrollment":1313},{"nctId":"NCT04007653","phase":"","title":"Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2017-04-25","conditions":"Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension","enrollment":1200},{"nctId":"NCT02610153","phase":"","title":"Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-10-01","conditions":"Atrial Fibrillation","enrollment":1013},{"nctId":"NCT02240667","phase":"","title":"Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09-18","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT02597920","phase":"","title":"Patient Convenience Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-11-11","conditions":"Atrial Fibrillation","enrollment":1852},{"nctId":"NCT03580577","phase":"","title":"Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09-01","conditions":"Liver Cirrhosis, Venous Thromboembolism","enrollment":60},{"nctId":"NCT03087474","phase":"","title":"Treatment of Venous Thromboembolism in Real-Life Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-04","conditions":"Venous Thromboembolism","enrollment":89383},{"nctId":"NCT03462446","phase":"","title":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-01","conditions":"Atrial Fibrillation","enrollment":249},{"nctId":"NCT02227550","phase":"PHASE4","title":"Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2014-12","conditions":"Atrial Fibrillation","enrollment":676},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT03276377","phase":"","title":"VItamin K Inhibition and NeurocoGnition (VIKING)","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2017-09","conditions":"Neurocognitive Disorders","enrollment":100},{"nctId":"NCT02376777","phase":"","title":"Comparison of Accidents and Their Circumstances With Oral Anticoagulants","status":"COMPLETED","sponsor":"CNGE IRMG Association","startDate":"2014-04","conditions":"Cardiovascular Complications, Hemorrhagic Disorders, Embolism and Thrombosis","enrollment":4162},{"nctId":"NCT02690155","phase":"","title":"Real-world Comparative Effectiveness of Rivaroxaban Versus VKA","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-12","conditions":"Atrial Fibrillation","enrollment":38831},{"nctId":"NCT02687867","phase":"","title":"Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-12","conditions":"Atrial Fibrillation","enrollment":56039},{"nctId":"NCT02687854","phase":"","title":"Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-12","conditions":"Atrial Fibrillation","enrollment":18591},{"nctId":"NCT01729871","phase":"PHASE3","title":"A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-02","conditions":"Atrial Fibrillation","enrollment":253},{"nctId":"NCT01029743","phase":"","title":"Xarelto Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Venous Thromboembolism","enrollment":3388},{"nctId":"NCT02090543","phase":"","title":"BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01","conditions":"Atrial Fibrillation","enrollment":647},{"nctId":"NCT02906527","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-10","conditions":"Non Valvular Atrial Fibrillation (nv AF)","enrollment":150000},{"nctId":"NCT02427516","phase":"","title":"Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-01","conditions":"Anticoagulation","enrollment":1144},{"nctId":"NCT02657616","phase":"","title":"Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA","status":"COMPLETED","sponsor":"Institut für Pharmakoökonomie und Arzneimittellogistik e.V.","startDate":"2015-12","conditions":"Atrial Fibrillation, Stroke Prophylaxis","enrollment":204464},{"nctId":"NCT02485873","phase":"","title":"Real-Life Evidence on Stroke Prevention in SPAF","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-05","conditions":"Atrial Fibrillation (Prevention of Stroke)","enrollment":8607},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT00395772","phase":"PHASE2","title":"Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-12","conditions":"Venous Thromboembolism","enrollment":543},{"nctId":"NCT01533441","phase":"PHASE2","title":"Vitamin K2 Intervention in Patients With Vitamin K Antagonists","status":"COMPLETED","sponsor":"Danisco","startDate":"2012-02","conditions":"Thrombosis","enrollment":50},{"nctId":"NCT00440193","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Venous Thrombosis","enrollment":3449},{"nctId":"NCT00439777","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Pulmonary Embolism","enrollment":4833},{"nctId":"NCT00645853","phase":"PHASE2","title":"Long-term Safety in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Persistent or Permanent Nonvalvular Atrial Fibrillation","enrollment":523},{"nctId":"NCT00623779","phase":"PHASE2","title":"Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Persistent or Permanent Non-valvular Atrial Fibrillation","enrollment":128},{"nctId":"NCT00067093","phase":"PHASE3","title":"Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-05","conditions":"Deep Vein Thrombosis","enrollment":1452},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":991,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Warfarin"],"phase":"phase_3","status":"active","brandName":"Vitamin K antagonists (VKA)","genericName":"Vitamin K antagonists (VKA)","companyName":"Population Health Research Institute","companyId":"population-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}